Provinces could save millions in prescription drug costs, new research finds

Taxpayers could save millions of dollars if hospitals and provincial governments harmonized their prescription drug plans, new research suggests.

Hospitals in Canada manage their formularies – the list of generic and brand-name drugs they dispense – independently. Yet many patients are discharged on medications they will have to purchase through publicly funded drug benefits programs.

Dr. Chaim Bell, a physician and researcher at St. Michael's Hospital and scientist at the Institute for Clinical Evaluative Sciences, noted that health care expenditures in Canada are on a steep upward climb, reaching $191 billion in 2010.

Medications represent an increasing share of those costs, currently around 16 per cent. A few classes of drugs account for the bulk of those expenses. For instance, the annual cost of angiotensin-converting enzyme (ACE) inhibitors in Canada doubled over the previous ten years to reach $956 million in 2006.

Dr. Bell decided to investigate how much public money could be saved if hospitals, when starting patients on new medications, prescribed the cheapest one. His results were published in the journal PLoS ONE today.

Using data from ICES, he looked at three commonly prescribed medications that account for a large chunk of prescription drug costs in Canada:

  • proton pump inhibitors (used to treat stomach ulcers and reflux acid)
  • ACE inhibitors and
  • angiotensin receptor blockers (both of which are used for high blood pressure, as well as treating heart failure and preventing kidney failure in diabetics)
The cost for filling all PPI, ACE inhibitor and ARB prescriptions in Ontario for one year, April 2008 to March 2009, was $2.48 million, $968,000 and $325,000 respectively.

Substituting the least expensive version of each drug could have saved $1.6 million, or 47 per cent, for PPIs, Dr. Bell found. It could have saved $162,000, or 17 per cent, for ACE inhibitors and $14,000, or four per cent, for ARBs in the year following the patients' discharge from hospital.

"At a time when every health care dollar matters and has to be spent wisely, these findings suggest that hospitals and governments should look at ways to break down the silos around prescription drug purchasing and dispensing," Dr. Bell said.

"It's all taxpayers' money. Whether it's billed to a hospital cost centre or a government drug plan cost centre, it all comes from the same source."

add to favorites email to friend print save as pdf

Related Stories

Myth busted: Some drugs do cost more in Canada

Sep 29, 2008

(PhysOrg.com) -- Canada may be recognized as a bargain hunters' paradise for prescription drugs, but a new U of T study suggests that many generic medications may be more expensive in Canada than in the U.S. The uninsured ...

Controlling the rising costs of cardiovascular care

Jan 24, 2011

Canada's health care system could have saved $77 million in 2006 if it had adopted a more restrictive policy on the cardiovascular drugs angiotensin receptor blockers without a negative impact on cardiovascular health, according ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments